Cargando…

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Obinutuzumab (GA101) is a novel glycoengineered type II CD20 antibody in development for non-Hodgkin lymphoma. We compared the anti-tumor activity of obinutuzumab and rituximab in preclinical studies using subcutaneous Z138 and WSU-DLCL2 xenograft mouse models. Obinutuzumab and rituximab were assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herting, Frank, Friess, Thomas, Bader, Sabine, Muth, Gunter, Hölzlwimmer, Gabriele, Rieder, Natascha, Umana, Pablo, Klein, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2014
Materias:	Original Article: Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196549/ https://www.ncbi.nlm.nih.gov/pubmed/24304419 http://dx.doi.org/10.3109/10428194.2013.856008

Ejemplares similares

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
por: Meneses-Lorente, Georgina, et al.
Publicado: (2015)

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
por: Tobinai, Kensei, et al.
Publicado: (2016)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
por: Ysebaert, L, et al.
Publicado: (2015)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL
por: Chu, Yaya, et al.
Publicado: (2020)

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial
por: Oughton, Jamie B., et al.
Publicado: (2017)

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment
por: Awasthi, Aradhana, et al.
Publicado: (2017)

The Applications of Metabolic Glycoengineering
por: Ying, Liwei, et al.
Publicado: (2022)

Genetic glycoengineering in mammalian cells
por: Narimatsu, Yoshiki, et al.
Publicado: (2021)

Strategies for Glycoengineering Therapeutic Proteins
por: Dammen-Brower, Kris, et al.
Publicado: (2022)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
por: Agez, Morgane, et al.
Publicado: (2019)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Cyclopropene derivatives of aminosugars for metabolic glycoengineering
por: Hassenrück, Jessica, et al.
Publicado: (2019)

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
por: Bakkour, Waseem, et al.
Publicado: (2012)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017)

Direct quality control of glycoengineered erythropoietin variants
por: Čaval, Tomislav, et al.
Publicado: (2018)

Applying Acylated Fucose Analogues to Metabolic Glycoengineering
por: Rosenlöcher, Julia, et al.
Publicado: (2015)

Protein Glycoengineering: An Approach for Improving Protein Properties
por: Ma, Bo, et al.
Publicado: (2020)

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
por: Li, Shasha, et al.
Publicado: (2021)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Disseminated Enteroviral Infection Associated with Obinutuzumab
por: Dendle, Claire, et al.
Publicado: (2015)

Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
por: Luo, Cheng, et al.
Publicado: (2017)

Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies
por: Tytgat, Hanne L. P., et al.
Publicado: (2019)

A versatile design platform for glycoengineering therapeutic antibodies
por: Ludwig, Seth D., et al.
Publicado: (2022)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis
por: Breakell, Thomas, et al.
Publicado: (2020)

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study
por: Gibiansky, Ekaterina, et al.
Publicado: (2019)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
por: Sethi, Supreet, et al.
Publicado: (2020)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Obinutuzumab: B-cell depletion: case report
Publicado: (2021)

IgG-Fc glycoengineering in non-mammalian expression hosts
por: Loos, Andreas, et al.
Publicado: (2012)

Labeling glycans on living cells by a chemoenzymatic glycoengineering approach
por: Almaraz, Ruben T., et al.
Publicado: (2017)

Glycoengineering Chinese hamster ovary cells: a short history
por: Donini, Roberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o38e8cvf3lskf5itk03r254ihv